| abstract |
Disclosed herein are compounds that form a covalent bond with Breton tyrosine kinase (Btk). Also described herein are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions comprising the compounds. Methods for using Btk inhibitors alone or in combination with other therapeutic agents for the treatment of autoimmune diseases or disorders, heterogeneous immune diseases or disorders, cancers including lymphoma, and inflammatory diseases or disorders Disclosed. [Selection figure] None |